While promising results with these drugs validate the concept of targeted therapy, the number of patients with these mutations is relatively small compared to the number of patients with mutations in TP53, RAS, and MYC. These are the most commonly mutated genes in human cancer, for which there are no effective targeted drugs available in the clinic today. Here, TP53 is linked to cancer.